Dr Rodziewicz studied medicine at The University of Manchester, completed an intercalated degree in Microbiology BSc and in her final year of medicine undertook a 4-month clinical placement in Madrid, Spain. She obtained her medical degree (MBChB with European Studies) in 2012.
Dr Rodziewicz began her rheumatology specialist training in South London and completed a Rheumatology MSc with distinction at King's College London in 2018. She is now a specialist trainee in the North West of England.
Statistical and biomarker approaches to identifying trajectories of response in patients with SLE: an observational study
Lupus is an incurable disease of the immune system that most commonly affects women of childbearing age. The medications used to treat lupus have not been well studied and can cause significant side effects. The variety of symptoms and the relative rarity of the disease make it difficult to study and because of this, there has only been one drug licensed to treat it in the past 50 years. The aim of this project is to work out how to predict which patients will not respond to standard treatments. This will help to identify which patients are most likely to benefit from new drugs in clinical trials.
Dr Rodziewicz will examine blood tests and other clinical information from three different groups of patients to see if she can predict how their disease activity will change over time. The first group includes individuals who have been treated as part of strictly controlled clinical trials carried out by pharmaceutical companies. The second will be ‘real life’ lupus patients from across the UK. The third, will be a smaller group of real-life patients who need a change in their treatment because of active disease.